Beruflich Dokumente
Kultur Dokumente
Immunity:
Innate, Natural Adaptive, Learned
IMMUNE MODIFIERS
Immunosuppressants
Immunostimulants
?Immune tolerance
Immune tolerance
Induction and maintenance of immunologic tolerance - active state of antigenic specific nonresponsiveness Still experimental
Immunosuppressants
Glucocorticoids Calcineurin inhibitors
Cyclosporine Tacrolimus
Antibodies
Antithymocyte globulin Anti CD3 monoclonal antibody
Muromonab
Immunostimulants
Levamisole Thalidomide BCG Recombinant Cytokines
Interferons Interleukin-2
Immunosuppressants
Organ transplantation Autoimmune diseases
Problem
Life long use Infection, cancers Nephrotoxicity Diabetogenic
This agent acts at multiple cellular sites to cause broad effects on inflammation and immune processes A. Tacrolimus B. Glucocorticoids C. Cyclophosphamide D. Azathioprine
This agent acts at multiple cellular sites to cause broad effects on inflammation and immune processes A. Tacrolimus B. Glucocorticoids C. Cyclophosphamide D. Azathioprine
Glucocorticoids
Induce redistribution of lymphocytes decrease in peripheral blood lymphocyte counts Intracellular receptors regulate gene transcription Down regulation of IL-1, IL-6 Inhibition of T cell proliferation Neutrophils, Monocytes display poor chemotaxis Broad anti-inflammatory effects on multiple components of cellular immunity
USES - Glucocorticoids
Transplant rejection GVH BM transplantation Autoimmune diseases RA, SLE, Hematological conditions Psoriasis Inflammatory Bowel Disease, Eye conditions
Toxicity
Growth retardation Avascular Necrosis of Bone Risk of Infection Poor wound healing Cataract Hyperglycemia Hypertension
The following is/are true for Cyclosporine A. Acts by inhibiting a cytoplasmic phosphatase through binding with cyclophilin B. known to cause hyperglycemia C. Used in solid organ transplant D. All of the above
The following is/are true for Cyclosporine A. Acts by inhibiting a cytoplasmic phosphatase through binding with cyclophilin B. known to cause hyperglycemia C. Used in solid organ transplant
Calcineurin inhibitors
Cyclosporine Tacrolimus
Most effective immunosuppressive drugs Target intracellular signaling pathways Blocks Induction of cytokine genes
bind to cyclophilin (for cyclosporine) or FKbinding protein (for tacrolimus) to inhibit calcineurin, a cytoplasmic phosphatase involved in signal transduction upon T-cell activation leading to gene transcription and consequently, cytokine expression.
Cyclosporine
More effective against T-cell dependent immune mechanisms transplant rejection, autoimmunity IV, Oral Erratic bioavailability Uses Organ transplantation: Kidney, Liver, Heart Rheumatoid arthritis, IBD, uveitis Psoriasis Aplastic anemia Skin Conditions- Atopic dermatitis, Alopecia Areata, Pemphigus vulgaris, Lichen planus, Pyoderma gangrenosum
Toxicity : Cyclosporine
Renal dysfunction Tremor Hirsuitism Hypertension Hyperlipidemia Gum hyperplasia Hyperuricemia worsens gout Calcineurin inhibitors + Glucocorticoids = Diabetogenic
Tacrolimus
Inhibits T-cell activation by inhibiting calcineurin Use
Prophylaxis of solid-organ allograft rejection Liver and kidney transplant
Toxicity - Tacrolimus
Nephrotoxicity Neurotoxicity-Tremor, headache, motor disturbances, seizures GI Complaints Hypertension Hyperglycemia Risk of tumors, infections Drug interaction
Synergistic nephrotoxicity with cyclosporine CYP3A4
Sirolimus
Inhibits T-cell activation and Proliferation Complexes with an immunophilin Inhibits a key enzyme in cell cycle progression mammalian target of rapamycin (mTOR) Kidney and heart transplant
Sirolimus
Uses Prophylaxis of organ transplant rejection along with other drugs Toxicity Increase in serum cholesterol, Triglycerides Anemia Thrombocytopenia Hypokalemia Fever GI effects (hepatotoxicity, diarrhea) Risk of infection, tumors Drug Interactions: CYP 3A4
Everolimus
Shorter half life compared to sirolimus Shorter time taken to reach steady state Similar toxicity, drug interactions
The dose of this drug should be decreased if the patient is concomitantly taking allopurinol A. Glucocorticoid B. Cyclophosphamide C. Azathioprine D. Methotrexate
The dose of this drug should be decreased if the patient is concomitantly taking allopurinol A. Glucocorticoid B. Cyclophosphamide C. Azathioprine D. Methotrexate
Azathioprine
Purine antimetabolite Incorporation of false nucleotide
6 Thio-IMP 6Thio-GMP 6Thio-GTP
Inhibition of cell proliferation Impairment of lymphocyte function Uses Prevention of organ transplant rejection Rheumatoid arthritis
Toxicity - Azathioprine
Bone marrow suppression- leukopenia, thrombocytopenia, anemia Increased susceptibility to infection Hepatotoxicity Alopecia GI toxicity Drug interaction: Allopurinol
Mycophenolate Mofetil
Prodrug Mycophenolic acid Inhibits IMPDH enzyme in guanine synthesis T, B cells are highly dependent on this pathway for cell proliferation Selectively inhibits lymphocyte proliferation, function Antibody formation, cellular adhesion, migration
Risk of Infection
Drug Interaction
Decreased absorption when coadministered with antacids Acyclovir, Gancyclovir compete with mycophenolate for tubular secretion
Toxicity
Lymphopenia Negative chronotropic effect
S1P-receptor on human atrial myocytes
Antibodies
Against lymphocyte cell-surface antigens Polyclonal / Monoclonal
Antibodies
Antithymocyte Globulin Monoclonal antibodies
Anti-CD3 Monoclonal antibody (Muromonab-CD3) Anti-IL-2 Receptor antibody (Daclizumab, Basiliximab) Campath-1H (Alemtuzumab)
Anti-TNF Agents
Infliximab Etanercept Adalimumab
Anti-thymocyte Globulin
Purified gamma globulin from serum of rabbits immunized with human thymocytes Cytotoxic to lymphocytes & block lymphocyte function Uses Induction of immunosuppression transplantation Treatment of acute transplant rejection Toxicity Hypersensitivity Risk of infection, Malignancy
Muromonab-CD3
Antibody treatment Rapid internalization of T-cell receptor Prevents subsequent antigen recognition
Uses
Treatment of acute organ transplant rejection Toxicity Cytokine release syndrome High fever, Chills, Headache, Tremor, myalgia, arthralgia, weakness Prevention: Steroids
Campath-1H (Alemtuzumab)
Targets CD52 expressed on lymphocytes, monocytes, Macrophages Extensive lympholysis Prolonged T & B cell depletion Uses Renal transplantation
Anti-TNF Agents
TNF Cytokine at site of inflammation Etanercept Infliximab Adalimumab
Etanercept
Fusion protein Ligand binding portion of Human TNF- receptor fused to Fc portion of human IgG1 Uses Rheumatoid arthritis
Infliximab
Uses Rheumatoid arthritis Chrons disease fistulae Psoriasis Psoriatic arthritis Ankylosing spondylosis Toxicity Infusion reaction fever, urticaria, hypotension, dyspnoea Opportunistic infections TB, RTI, UTI
SITE OF ACTION
Glucocorticoid response elements in DNA (regulate gene transcription) CD3T-cell receptor complex (blocks antigen recognition) Calcineurin (inhibits phosphatase activity) Calcineurin (inhibits phosphatase activity) Deoxyribonucleic acid (false nucleotide incorporation) Inosine monophosphate dehydrogenase (inhibits activity) IL-2 receptor (block IL-2-mediated T-cell activation) Protein kinase involved in cell-cycle progression (mTOR) (inhibits activity)
Daclizumab, Basiliximab
Sirolimus
Immunostimulants
Levamisole Thalidomide BCG Recombinant Cytokines
Interferons Interleukin-2
An immunostimulant drug which is currently used for bladder CA is A. Levimasole B. Imatinib C. BCG D. Interleukin alpha
An immunostimulant drug which is currently used for bladder CA is A. Levimasole B. Imatinib C. BCG D. Interleukin alpha
Levamisole
Antihelminthic Restores depressed immune function of B, T cells, Monocytes, Macrophages Adjuvant therapy with 5FU in colon cancer Toxicity Agranulocytosis
Thalidomide
Birth defect Contraindicated in women with childbearing potential Enhanced T-cell production of cytokines IL-2, IFN- NK cell-mediated cytotoxicity against tumor cells USE: Multiple myeloma
Bacillus Calmette-Guerin
Live, attenuated culture of BCG strain of Mycobacterium Bovis Carcinoma Bladder Adverse Effects
Hypersensitivity Shock Chills
Interferons
Antiviral Immunomodulatory activity Bind to cell surface receptors initiate intracellular events
Enzyme induction Inhibition of cell proliferation Enhancement of immune activities Increased Phagocytosis
Interferon alfa-2b
Hairy cell leukemia Malignant melanoma Kaposi sarcoma Hepatitis B
Adverse reactions Flu-like symptoms fever, chills, headache CVS- hypotension, Arrhythmia CNS- depression, confusion
Interleukin-2 (aldesleukin)
Proliferation of cellular immunity Lymphocytosis, eosinophilia, release of multiple cytokines TNF, IL-1, IFN-
Uses Metastatic renal cell carcinoma Melanoma Toxicity Cardiovascular: capillary leak syndrome, Hypotension
Immune Globulin
Indications Individual is deficient in antibodies immunodeficiency Individual is exposed to an agent, inadequate time for active immunization
Rabies Hepatitis B
Nonspecific immunoglobulins
Antibody-deficiency disorders
Summary
Immunosuppresion
Calcineurin inhibitors Glucocorticoids Antimetabolites
A drug indicated for treatment of moderate to severe rheumatoid arthritis but not appropriate for treating moderate to severe osteoarthritis is A. Acetaminophen B. Etanercept C.Ibuprofen D. Rofecoxib
A drug indicated for treatment of moderate to severe rheumatoid arthritis but not appropriate for treating moderate to severe osteoarthritis is A. Acetaminophen B. Etanercept C.Ibuprofen D. Rofecoxib